<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043923</url>
  </required_header>
  <id_info>
    <org_study_id>NKT-202</org_study_id>
    <nct_id>NCT04043923</nct_id>
  </id_info>
  <brief_title>Norketotifen for the Treatment of Uncomplicated Influenza-like Illness</brief_title>
  <official_title>A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled,&#xD;
      parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute&#xD;
      uncomplicated ILI due to influenza or other respiratory viruses in a community setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to alleviation of symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose symptoms have been alleviated at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in composite symptom score at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever (body temperature equal to or less than 37ºC)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature at each time point through Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of individual symptoms (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resumption of normal activity</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication (acetaminophen)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Influenza -Like Illness</condition>
  <arm_group>
    <arm_group_label>Norketotifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norketotifen oral capsules, once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsules, once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Norketotifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand the study and comply with all study procedures, and willing to&#xD;
             provide written informed consent prior to the pre-dose examinations&#xD;
&#xD;
          2. Symptoms of ILI including all of the following:&#xD;
&#xD;
               -  Fever ≥38º Celsius (oral) in the predose examinations or &gt;4 hours after dosing of&#xD;
                  antipyretics if they were taken&#xD;
&#xD;
               -  At least one of the following general systemic symptoms associated with ILI are&#xD;
                  present with a severity of moderate or greater: headache, feverishness or chills,&#xD;
                  muscle or joint pain, fatigue&#xD;
&#xD;
               -  At least one of the following respiratory symptoms associated with ILI are&#xD;
                  present with a severity of moderate or greater: cough, sore throat, nasal&#xD;
                  congestion&#xD;
&#xD;
          3. The time interval between the onset of symptoms and the predose examinations is ≤96&#xD;
             hours. The onset of symptoms is defined as either:&#xD;
&#xD;
               -  Time of the first increase in body temperature (an increase of at least 1º&#xD;
                  Celsius from normal body temperature)&#xD;
&#xD;
               -  Time when the subject experiences at least one general or respiratory symptom&#xD;
&#xD;
          4. Females of childbearing potential and males agree to use an appropriate method of&#xD;
             contraception as detailed in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant, 2 weeks post-partum, or breastfeeding&#xD;
&#xD;
          2. Severe ILI requiring inpatient treatment&#xD;
&#xD;
          3. Any of the following risk factors (according to the CDC's list of People at High Risk&#xD;
             for Developing Serious Flu-Related Complications):&#xD;
&#xD;
               -  Residents of nursing homes or other long-term care facilities&#xD;
&#xD;
               -  American Indians and Alaska natives&#xD;
&#xD;
               -  Asthma&#xD;
&#xD;
               -  Chronic lung disease (such as chronic obstructive pulmonary disease or cystic&#xD;
                  fibrosis)&#xD;
&#xD;
               -  Neurological and neurodevelopmental conditions (including disorders of the brain,&#xD;
                  spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy&#xD;
                  [seizure disorders], stroke, intellectual disability, moderate to severe&#xD;
                  developmental delay, muscular dystrophy, or spinal cord injury)&#xD;
&#xD;
               -  Heart disease (such as congenital heart disease, congestive heart failure, or&#xD;
                  coronary artery disease)&#xD;
&#xD;
               -  Blood disorders (such as sickle cell disease)&#xD;
&#xD;
               -  Endocrine disorders (such as diabetes mellitus)&#xD;
&#xD;
               -  Kidney disorders&#xD;
&#xD;
               -  Liver disorders&#xD;
&#xD;
               -  Metabolic disorders (such as inherited metabolic disorders and mitochondrial&#xD;
                  disorders)&#xD;
&#xD;
               -  Compromised immune system due to disease or medication (such as subjects with&#xD;
                  human immunodeficiency virus or cancer, or those on chronic steroids)&#xD;
&#xD;
               -  Extreme obesity (body mass index ≥40 kg/m^2)&#xD;
&#xD;
          4. Presence of any severe or uncontrolled medical or psychiatric illness&#xD;
&#xD;
          5. History of or current autoimmune disease&#xD;
&#xD;
          6. History of recurrent lower respiratory tract infection&#xD;
&#xD;
          7. Any concurrent infection requiring systemic antimicrobial and/or antiviral therapy&#xD;
&#xD;
          8. Female subjects who are pregnant or breastfeeding&#xD;
&#xD;
          9. Any clinically significant electrocardiogram test&#xD;
&#xD;
         10. Received baloxavir, oseltamivir, peramivir, zanamivir, rimantadine, or amantadine&#xD;
             within 30 days prior to the pre-dose examinations&#xD;
&#xD;
         11. Received an investigational monoclonal antibody for a viral disease in the last year&#xD;
             prior to the pre-dose examinations&#xD;
&#xD;
         12. Received ketotifen fumarate, cromolyn sodium, or nedocromil sodium by any route of&#xD;
             administration within 30 days prior to the pre-dose examinations&#xD;
&#xD;
         13. Exposure to an investigational drug within 30 days prior to the pre-dose examinations&#xD;
&#xD;
         14. History of allergic reaction to ketotifen&#xD;
&#xD;
         15. Any prior exposure to norketotifen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cahaba Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trial Services</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research Associate</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Medical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CityDoc Urgent Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <disposition_first_submitted>March 22, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 24, 2021</disposition_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

